Insulet Co. (NASDAQ:PODD) Holdings Increased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in Insulet Co. (NASDAQ:PODD - Free Report) by 5.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 407,592 shares of the medical instruments supplier's stock after purchasing an additional 22,247 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.58% of Insulet worth $88,439,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. increased its position in shares of Insulet by 18.2% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,024 shares of the medical instruments supplier's stock worth $482,000 after acquiring an additional 466 shares during the period. Raymond James & Associates grew its stake in shares of Insulet by 3.8% during the third quarter. Raymond James & Associates now owns 56,215 shares of the medical instruments supplier's stock worth $8,966,000 after purchasing an additional 2,041 shares in the last quarter. Mackenzie Financial Corp grew its stake in shares of Insulet by 2.2% during the third quarter. Mackenzie Financial Corp now owns 5,601 shares of the medical instruments supplier's stock worth $878,000 after purchasing an additional 123 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Insulet by 43.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,353 shares of the medical instruments supplier's stock worth $3,724,000 after purchasing an additional 7,044 shares in the last quarter. Finally, TD Asset Management Inc grew its stake in shares of Insulet by 43.1% during the third quarter. TD Asset Management Inc now owns 82,928 shares of the medical instruments supplier's stock worth $13,226,000 after purchasing an additional 24,959 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages recently commented on PODD. Jefferies Financial Group boosted their target price on shares of Insulet from $255.00 to $260.00 and gave the stock a "buy" rating in a research note on Friday. JPMorgan Chase & Co. upped their price objective on shares of Insulet from $190.00 to $225.00 and gave the company an "overweight" rating in a research note on Friday, February 23rd. Barclays decreased their price objective on shares of Insulet from $213.00 to $200.00 and set an "equal weight" rating for the company in a research note on Monday. Stifel Nicolaus upped their price objective on shares of Insulet from $163.00 to $208.00 and gave the company a "hold" rating in a research note on Monday, February 5th. Finally, Canaccord Genuity Group upped their price objective on shares of Insulet from $226.00 to $234.00 and gave the company a "buy" rating in a research note on Friday. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average price target of $239.44.

Insulet Price Performance

Insulet stock traded down $4.88 during mid-day trading on Monday, reaching $161.02. The company had a trading volume of 1,749,438 shares, compared to its average volume of 896,548. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $331.65. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75. The company has a market capitalization of $11.27 billion, a P/E ratio of 48.79, a P/E/G ratio of 2.91 and a beta of 1.00. The stock's 50-day simple moving average is $170.39 and its 200-day simple moving average is $182.53.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, beating the consensus estimate of $0.39 by $0.34. The business had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The company's quarterly revenue was up 23.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.23 earnings per share. On average, equities analysts predict that Insulet Co. will post 3.16 EPS for the current year.

Insider Activity

In other news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.47% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.